Ponte di Legno Working Group: statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop

This publication has 75 references indexed in Scilit:

• Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia
  Blood, 2003
• Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)
  Leukemia, 2003
• FLT3: ITDoes matter in leukemia
  Leukemia, 2003
• Origins of chromosome translocations in childhood leukaemia
  Nature Reviews Cancer, 2003
• DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers
  Leukemia, 2003
• A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
  Blood, 2002
• Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia
  The Lancet, 2001
• Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
  New England Journal of Medicine, 2001
• Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Acute Lymphoblastic Leukemia Studies, 1982–1995
  Leukemia, 2000
• The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the Medical Research Council UKALLR1 study
  British Journal of Haematology, 2000